Clinical Trial Update: Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) [Phase 4]

View source ↗

Summary

Phase 4 AMA-VACC trial results assess the immune response to SARS-CoV-2 modRNA vaccines in patients with secondary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• SARS-CoV-2 modRNA vaccine

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Secondary Progressive Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2024-05-17